WednesdayAug 31, 2022 12:47 pm

Ways to Prevent a Child from Choking

Children are prone to various accidents that can occur anywhere and at any time. Among the most common of these accidents is choking, which occurs when a child’s airway is obstructed. Unlike an adult’s airway, a child’s airway is smaller, which means it can easily be blocked. Figures show that an estimated 40 children are admitted to emergency rooms for choking, with one child losing their life by choking on food every five days in America. Below, we look at various choking hazards you should be aware of and what foods you can avoid as well as how to prevent…

Continue Reading

WednesdayAug 31, 2022 11:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Pioneering Efforts as Studies, Research Show Psilocybin’s Potential in Treating AUD

A new study shows promise in treating alcohol addiction with psychedelic mushroom compound, psilocybin These results align with efforts and expectations of Cybin, a leading ethical biopharmaceutical company championing psilocybin After receiving FDA approval, the company is moving forward with a first-in-human clinical trial evaluating CYB003 A new study published in JAMA Psychiatry offers hope for those struggling with alcoholism (https://ibn.fm/jV5o9), showing promise in treating alcohol addiction with the psychedelic compound psilocybin. This news aligns with initiatives of Cybin (NEO: CYBN) (NYSE American: CYBN), a leading ethical biopharmaceutical company, which has a drug in development, CYB003, for the treatment of alcohol…

Continue Reading

TuesdayAug 30, 2022 11:44 am

Study Finds Children Have Better Outcomes with Kidney Transplants from Living Donors

A new study has found that pediatric patients who undergo kidney transplants may have better outcomes if the donated kidney comes from a biologically unrelated and living donor in comparison to a deceased donor. For their research, the scientists reviewed data obtained from the Organ Procurement and Transplantation Network database during the period between January 2001 and September 2021. The investigators examined more than 12,000 children who had received kidney transplants during the study period. Of the total number of children, 61% received kidneys from deceased donors, 36% received kidneys from living related donors and less than 3% received kidneys…

Continue Reading

TuesdayAug 30, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking to Fill Glioblastoma Multiforme Treatment Gap with Berubicin Drug Product

CNS Pharmaceuticals is currently undertaking a potentially pivotal global study evaluating the efficacy and safety of Berubicin compared with Lomustine administered after first-line therapy for the treatment of recurrent glioblastoma multiforme (“GBM”) GBM is an aggressive form of cancer that occurs in the brain or spinal cord In the U.S., it affects between 12,000-15,000 new patients annually with a median survival rate of only 14.6 months from its diagnosis CNS’s drug development program is targeting the GBM drug market which is expected to expand at a CAGR of more than 4% between 2020 and 2030 On July 24, 2021, pre-clinical…

Continue Reading

MondayAug 29, 2022 11:48 am

Study Looks into Why Deadly Brain Tumors Continue to Grow After Treatment

Gliomas are rare and fatal brain tumors that form when glial cells in the body grow uncontrollably. Glial cells usually support nerves in the body by helping an individual’s central nervous system function. These deadly tumors typically grow in the brain but may, in some cases, also grow in the spinal cord. New research has discovered that gliomas adapt to their surrounding brain environment in response to cancer treatment, developing interactions with nearby immune cells and neurons that prevent tumor cells from being identified easily by the body’s immune system. The study was conducted by an international team of experts,…

Continue Reading

FridayAug 26, 2022 11:46 am

Study Explains How Threatening Cues Are Refined into Fear Signals

The fight-or-flight response is synonymous with most life forms. In moments of acute stress, your sympathetic nervous system will activate a sudden release of hormones that trigger a single response: fight or flight. Fear plays a major role in activating this response because it is usually activated in dire moments when a quick decision could be the difference between life and death. Scientists from the Salk Institute who were researching how the brain gathers threatening cues and distills them into fear signals have found a molecular pathway that plays a major role in creating the fear response. This pathway distills…

Continue Reading

FridayAug 26, 2022 9:45 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Transformation of Psychedelic Sector

Psilocybin is seeing a “research resurgence” focused on how the substance changes the brain's connectivity patterns CYBN is leading the industry in developing proprietary psychedelic-based therapeutics The company’s lead investigational molecule has the potential to treat major depressive disorder and alcohol use disorder The status of psilocybin is evolving as a result of mounting public acceptance and growing evidence that the substance delivers remarkable health benefits. Cybin (NEO: CYBN) (NYSE American: CYBN) is on the leading edge of this transformation, as the clinical-stage biopharmaceutical company focuses on progressing psychedelics to therapeutics by offering a new standard of care for mental-health disorders…

Continue Reading

ThursdayAug 25, 2022 11:34 am

Israeli Study identifies Bacterial Footprint in PTSD Sufferers

A new study has found that saliva samples can be used to accurately and rapidly diagnose individuals suffering from post-traumatic stress disorder, or PTSD. PTSD is a mental health condition that is triggered by an individual witnessing or experiencing a terrifying event. The study was carried out by scientists from the Tel Aviv University and the University of Haifa in Israel. For their research, the scientists obtained samples of saliva from some 200 Israeli soldiers and studied their medical, social and psychological conditions. The research, which was led by Professor Illana Gozes of the Sackler Faculty of Medicine, found that…

Continue Reading

ThursdayAug 25, 2022 10:30 am

Phase I Trial Advance for Concussion Drug Leads Odyssey Health, Inc. (ODYY) to Prepare to Launch the Efficacy Analysis Stage for its Product

Brain concussion injuries have commanded a new level of respect in recent years as military personnel, athletes and care center administrations seek remedies rather than simply encouraging people to “shake off” a hard hit to the head Odyssey Health is advancing clinical trials for its novel PRV-002 drug / device solution for treating concussion patients The company reported completion of four cohorts of testing for safety in human subjects in August, and is preparing to launch Phase II testing that will evaluate the product’s efficacy PRV-002 is administered intranasally where it can be taken up across the blood-brain barrier by…

Continue Reading

WednesdayAug 24, 2022 11:40 am

Study Finds Patients with Hodgkin’s Lymphoma Have Higher Risk of Developing Mental Illnesses

New research has found that Hodgkin’s lymphoma patients have a higher likelihood of suffering from substance-abuse and mental health disorders, in comparison to the general population. Hodgkin’s lymphoma works by attacking an individual’s immune system. The highly curable cancer is said to be prevalent in those aged between 15 and 39. This cancer type affects young individuals going through major transitions and events in their lives, such as starting their careers and attending college. Data from the National Cancer Institute shows that in the last five decades, death from Hodgkin’s lymphoma has dramatically reduced in comparison to any other cancer.…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050